(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 September 2019 (19.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/178426 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61K 31/712 (2006.01) *C12N 5/10* (2006.01)

(21) International Application Number:
PCT/US2019/022374

(22) International Filing Date:
14 March 2019 (14.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/643,168 14 March 2018 (14.03.2018) US
62/767,488 14 November 2018 (14.11.2018) US
62/773,073 29 November 2018 (29.11.2018) US

(71) Applicant: **EDITAS MEDICINE, INC.** [US/US]; 11 Hurley Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **GORI, Jennifer Leah**; 20 Spalding Street, Unit 1, Jamaica Plain, Massachusetts 02130 (US). **AUPEPIN DE LAMOTHE-DREUZY, Edouard**; 123 Pinckney Street, Boston, Massachusetts 02114 (US). **HEATH, Jack**; 1 Wildwood Street, Winchester, Massachusetts 01890 (US). **ZURIS, John Anthony**; 8 Manley Street, Unit 2, Boston, Massachusetts 02122 (US). **CHANG, KaiHsin**; 113 Wood End Lane, Medfield, Massachusetts 02052 (US).

(74) Agent: **MORRIS, Patrick D.** et al.; c/o Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

FIG 1



(57) Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the *HBG1* and *HBG2* loci, portions of the erythroid specific enhancer of the *BCL11A* gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.

WO 2019/178426 A1